Syneos Health Inc (NASDAQ:SYNH) – Equities research analysts at Mitsubishi UFJ Financial Group issued their FY2021 EPS estimates for Syneos Health in a research report issued on Tuesday, March 19th, according to Zacks Investment Research. Mitsubishi UFJ Financial Group analyst J. Twizell expects that the company will post earnings per share of $3.50 for the year.
A number of other brokerages have also weighed in on SYNH. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. UBS Group lowered Syneos Health from a “buy” rating to a “neutral” rating and set a $55.00 target price for the company. in a research note on Tuesday, March 19th. Wolfe Research began coverage on Syneos Health in a research note on Tuesday, April 2nd. They issued a “market perform” rating for the company. Credit Suisse Group raised their target price on Syneos Health from $49.00 to $51.00 and gave the company an “outperform” rating in a research note on Tuesday, March 19th. Finally, William Blair restated an “outperform” rating on shares of Syneos Health in a research note on Tuesday, March 19th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $52.70.
Syneos Health (NASDAQ:SYNH) last released its quarterly earnings data on Monday, March 18th. The company reported $0.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.16. Syneos Health had a return on equity of 9.60% and a net margin of 0.55%. The firm had revenue of $1.15 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company posted $0.70 earnings per share. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year.
In related news, CEO Alistair Macdonald sold 8,143 shares of the firm’s stock in a transaction dated Wednesday, February 13th. The stock was sold at an average price of $53.00, for a total value of $431,579.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.57% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in Syneos Health by 7.3% in the fourth quarter. Geode Capital Management LLC now owns 738,567 shares of the company’s stock valued at $29,061,000 after acquiring an additional 50,175 shares during the last quarter. Norges Bank bought a new position in Syneos Health in the fourth quarter valued at about $24,850,000. Nordea Investment Management AB boosted its holdings in Syneos Health by 1.9% in the fourth quarter. Nordea Investment Management AB now owns 152,748 shares of the company’s stock valued at $6,010,000 after acquiring an additional 2,885 shares during the last quarter. Amalgamated Bank boosted its holdings in Syneos Health by 3.4% in the fourth quarter. Amalgamated Bank now owns 8,877 shares of the company’s stock valued at $349,000 after acquiring an additional 293 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its holdings in Syneos Health by 2.7% in the fourth quarter. Macquarie Group Ltd. now owns 58,157 shares of the company’s stock valued at $2,288,000 after acquiring an additional 1,512 shares during the last quarter.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.